When PARPi acts on BRCA-mutated cancer cells, it causes synthetic lethality through inhibition of the DDR pathway, while simultaneously inhibiting meiotic recombination 11 (MRE11), which degrades RF by blocking its interaction. Here, MRE11 is linked to cancer.